AnaptysBio (NASDAQ:ANAB) Upgraded to “Strong-Buy” at UBS Group

UBS Group upgraded shares of AnaptysBio (NASDAQ:ANAB) to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

Several other research analysts have also commented on the company. Stifel Nicolaus decreased their target price on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Truist Financial boosted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, November 10th. Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Finally, HC Wainwright decreased their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a report on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.40.

AnaptysBio Stock Performance

ANAB opened at $43.80 on Wednesday. The company has a market capitalization of $1.21 billion, a P/E ratio of -15.53 and a beta of 0.32. The company has a 50-day moving average of $42.46 and a 200-day moving average of $31.30. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $52.47.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. As a group, sell-side analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has authorized a share buyback program on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In other news, Director J. Anthony Ware sold 3,900 shares of AnaptysBio stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $49.58, for a total transaction of $193,362.00. Following the sale, the director owned 9,630 shares of the company’s stock, valued at approximately $477,455.40. The trade was a 28.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Paul F. Lizzul sold 4,219 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $182,513.94. Following the transaction, the insider owned 33,303 shares of the company’s stock, valued at approximately $1,440,687.78. This represents a 11.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 112,624 shares of company stock worth $5,171,459 over the last three months. Insiders own 33.50% of the company’s stock.

Institutional Trading of AnaptysBio

Hedge funds have recently added to or reduced their stakes in the business. Larson Financial Group LLC boosted its position in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the period. Rhumbline Advisers increased its holdings in shares of AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after purchasing an additional 826 shares during the period. Bessemer Group Inc. raised its stake in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Corton Capital Inc. lifted its holdings in AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 1,305 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro (a GSK subsidiary)’s anticipatory breach claim in Delaware Chancery Court, which, if sustained, could reduce near‑term royalty exposure tied to Jemperli sales and lower legal risk. Reuters: AnaptysBio seeks partial dismissal GlobeNewswire: Motion to dismiss filing
• Positive Sentiment: Recent fundamentals and capital actions remain supportive: Anaptys reported an earnings and revenue beat in November and its board authorized up to $100M in share repurchases, which can support the share price over time by signaling management confidence and reducing outstanding float. MarketBeat ANAB coverage
• Neutral Sentiment: Upcoming event: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference (Jan. 13), which could catalyze new corporate updates or guidance but is unlikely to move the stock absent specific news. GlobeNewswire: JPM presentation
• Neutral Sentiment: Institutional positioning: Several funds have added or initiated positions recently, which can provide longer‑term demand but also increases the potential for large block trades to move the stock. MarketBeat ownership data
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and CFO) disclosed sizable sales on Jan. 5–7 that materially reduced their holdings; public Form 4 filings and media reports of these sales are likely contributing to today’s downward pressure as some investors view clustered insider sales negatively. InsiderTrades: insider selling alerts

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.